A derivative of epigallocatechin‐3‐gallate induces apoptosis via SHP‐1‐mediated suppression of BCR‐ABL and STAT3 signalling in chronic myelogenous leukaemia

Publisher： John Wiley & Sons Inc

E-ISSN： 1476-5381|172|14|3565-3578

ISSN： 0007-1188

Source： BRITISH JOURNAL OF PHARMACOLOGY (ELECTRONIC), Vol.172, Iss.14, 2015-07, pp. : 3565-3578

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Acute Lymphoblastic Leukaemia with an e1a3 BCR-ABL1 Fusion

By  

Acta Haematologica, Vol. 126, Iss. 4, 2011-09 ,pp. : 214-215

Karger

Access to resources Recommend Favorite

A Rare, In-Frame BCR-ABL Fusion (e13a3) in a Patient with an Aggressive Chronic Myeloid Leukaemia

By  

Acta Haematologica, Vol. 108, Iss. 3, 2002-09 ,pp. : 150-153

Karger

Access to resources Recommend Favorite

Elevated platelet count features the variant type of BCR/ABL junction in chronic myelogenous leukaemia

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 7-1048, Iss. 2, 1996-08 ,pp. : 370-372

John Wiley & Sons Inc

Access to resources Recommend Favorite

Elevated platelet count features the variant type of BCR/ABL junction in chronic myelogenous leukaemia

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 94, Iss. 2, 1996-08 ,pp. : 370-372

John Wiley & Sons Inc

Access to resources Recommend Favorite

BCR-ABL in Chronic Myelogenous Leukemia – How Does It Work?

By  

Acta Haematologica, Vol. 119, Iss. 4, 2008-06 ,pp. : 212-217

Karger

Access to resources Recommend Favorite